c-erbB-2 is an oncoprotein which is overexpressed in some breast cancers. Recently it has been established that the extracellular domain of c-erbB-2 is shed into the serum of patients with breast cancer. There appears to be no association between tumor stage and extracellular domain of c-erbB-2 (c-erbB-2/ECD): c-erbB-2/ECD seems to correlate with patient prognosis whenever the stage of disease. The data also suggest that c-erbB-2/ECD may be useful in monitoring for tumor recurrence and in predicting resistance to hormonal therapy, but not as useful in predicting response to chemotherapy. This may relate to the power of this marker to reflect disease burden, which has an overwhelmingly negative impact on outcome.
CITATION STYLE
Harris, L., Luftner, D., Jäger, W., & Robertson, J. F. R. (1999). c-erbB-2 in serum of patients with breast cancer. In International Journal of Biological Markers (Vol. 14, pp. 8–15). Wichtig Editore s.r.l. https://doi.org/10.1177/172460089901400103
Mendeley helps you to discover research relevant for your work.